霍奇金淋巴瘤化疗前后血清蛋白指纹图谱的变化

Changes of the serum proteome profiles in pre-and post-chemotherapy Hodgkin lymphoma patients

目的:探讨霍奇金淋巴瘤(Hodgkin lymphoma,HL)患者化疗前后血清蛋白指纹图谱变化,以寻找与其疗效有关的血清蛋白生物标记。方法:应用表面增强激光解析离子飞行时间质谱技术(SELDI-TOF-MS)检测18例初诊和16例化疗后HL患者血清,并取21例正常对照的血清,用CM10蛋白芯片获得血清蛋白表达指纹图谱,用Biomark-er Wizard3.1软件对检测数据进行统计学分析。结果:化疗前后HL患者差异表达31个蛋白质M/Z,其中有25个蛋白质在化疗后HL血清高表达,有6个蛋白质低表达;化疗后HL和正常对照存在3个没有统计差异的蛋白质。结论:应用SELDI-TOF-MS可筛选HL患者血清中的标志蛋白,可为HL患者诊断、分期、多药耐药性检测、疗效判断以及早期复发预测等方面提供客观有用的信息。

Objective： To explore the serum proteome profiles changes of pre-and post-chemotherapy Hodgkin lymphoma patients,and to search the serum biomarkers for the therapeutic effect of HL.Methods： Surface-enhanced lastexdesorption/ionization-time of flight-mass spectra（SELDI-TOF-MS） was used to detect the sera of 34 HL patients and 21 control cases,18 newly diagnosised patients and 16 post-chemotherapy patients.The Biomarker Wizard 3.1 system software was applied to analyze the data from the serum protein mass spectra by CM10 proteinchip array.Results： Thirty-one protein mass peaks were found differently expressed between the sera of newly diagnosised and post-chemotherapy HL patients.Twenty-five proteins were up-regulated and six down-regulated in sera of post-chemotherapy HL cases.Thirty proteins are found no differently expressed between the sera of post-chemotherapy HL patients and control ones.Conclusion： SELDI-TOF-MS may be used to screen the serum biomarkers of HL and might provide objective useful information for diagnosising,staging,detecting MRD,and to judge therapeutic effect,and predict earlier relapse of HL.